MedTrace Logo

Drug Interaction Study of ASC42 With Atorvastatin

NCT05464628 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-09-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether ASC42 alters the pharmacokinetics of atorvastatin in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Atorvastatin

Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin

DRUG

ASC42

Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin

Sponsors & Collaborators

  • Gannex Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-08
Primary Completion
2022-08-23
Completion
2022-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05464628 on ClinicalTrials.gov